56 results about "VZV - Varicella-zoster virus" patented technology

The present invention relates to the identification of the active domain of Herpoxin, a DNA virus-inhibiting-protein which was isolated from cobra venom in U.S. Pat. No. 5,648,339 and has a molecular weight of 13.5 kDa We have isolated a fragment of Herpoxin which contains the active domain and which we have named Herp. Herp mimics the activity of Herpoxin in inhibiting the replication of DNA viruses. A synthetic version of the active fragment was produced having the amino acid sequence Asn-Leu-Tyr-Gln-Phe-Lys-Asn-Met-Ile-Gln. The synthetic version of Herp consisting of ten amino acids inhibits the replication of DNA viruses such as herpes viruses types 1 and 2, cytomegalovirus and varicella zoster virus as well as Tubercle bacilli.

The invention discloses an application of polycyclic polyketides in preparation of an anti-HV (herpes virus) drug. It is found that the polyketides can inhibit diseases caused by infection of four HVs including HSV-1 (herpes simplex virus-1), HSV-2 (herpes simplex virus-2), VZV (varicella zoster virus) and CMV (cytomegalo virus). The compounds show equivalent activity but have different acting mechanisms as compared with commercial drugs such as acyclovir and can overcome drug resistance of existing commercial drugs. Therefore, the compounds have good application prospects in treatment of related diseases caused by infection of HVs including HSV-1, HSV-2, VZV and CMV.

The present invention provides novel antibody sequences that bind Varicella Zoster Virus (VZV) and neutralize VZV infection. The novel sequences can be used for the medical management of VZV infection, in particular for detecting the virus or for preparing pharmaceutical compositions to be used in the prophylactic or therapeutic treatment of VZV infection.

The invention provides a kit for genotyping VZV (Varicella-Zoster Viruses). The kit is characterized by comprising a nucleotide sequence shown as the Table 3 in the specification, and specific primers and specific probes corresponding to clade1-5 type VZV of chemical structures. The kit has the function of detecting various kinds of VZV DNA (Deoxyribonucleic Acid); the detection sensitivity is 10<2> copies / reaction; no cross reaction with human genome, herpes simplex viruses type I / type II, cytomegaloviruses and EB viruses exists; and the kit is applicable to the virus gene diagnosis of clinical VZV infected persons, and can also be used for the epidemiology survey of different Clade types of VZV.

The present invention generally relates to a molecular test of enterovirus, herpes simplex virus-1 and -2, and / or Varicella-Zoster virus, in order to identify patients with a viral infection, in particular a viral infection of the central nervous system. Accordingly methods and compositions are disclosed to determine the presence or absence of a viral pathogen in a biological sample comprising, wherein the target nucleic acids comprise the 5′ UTR of the enterovirus genome, UL29 of herpes simplex virus and gene 36 of Varicella-Zoster virus.

The invention discloses a varicella-zoster virus gE glycoprotein antigen capable of detecting an anti-varicella-zoster virus antibody, particularly an anti-varicella-zoster virus neutralizing antibody, and also discloses application of the antigen in the preparation of a detection reagent for detecting the anti-varicella-zoster virus neutralizing antibody and a corresponding detection reagent kit.

The present invention is directed to a mutated recombinant herpesvirus, e.g., varicella zoster virus (VZV) and simian varicella virus strains or HSV-1 or HSV-2 strains, vaccines containing, and methods for the construction and use thereof to elicit protective immunity in susceptible individuals, wherein the particular herpesvirus is modified to render the virus replication deficient, i.e., the virus substantially or only replicates under defined conditions, by the incorporation of at least one destabilization domain in or fused to a gene essential for herpesvirus replication. The invention particularly relates to the use of the resultant conditionally replication defective herpesviruses, e.g., a mutated VZV strains in vaccine compositions in order to immunize individuals against herpesvirus infection, e.g., in the case of VZV chickenpox and to protect against shingles and zoster, or to prevent the reactivation of VZV or other herpesvirus reactivation and the onset of shingles or another condition relating to the reactivation of another herpesvirus infection, e.g., as a consequence of advanced age, stress, inflammation, drug or other therapy, cancer, or immunodeficiency such as in HIV-AIDS or other diseases resulting in impaired T and / or B cell immunity.

A recombinant varicella-zoster virus; a process for producing the same; a pharmacological composition containing recombinant varicella-zoster virus; a vector containing a genomic gene of varicella-zoster virus and BAC vector sequence; cells containing the above vector; a fragment capable of homologous recombination with a genome of varicella-zoster virus; and a nucleic acid cassette containing the BAC vector sequence. For these, there is provided a process for producing recombinant varicella-zoster virus, comprising use of the BAC vector sequence.

The invention relates to the technical field of in-vitro diagnostic reagents and particularly relates to a kit capable of determining the titer of neutralizing antibodies of varicella-zoster viruses and a production method thereof. The kit adopts cells infected by VZV as antigens, is coated and fixed in holes of a 96-pore plate, the neutralizing antibodies in the sample to be determined are captured by using a large amount of virus glycoprotein (neutralizing glycoprotein) carried on the surfaces of the cells, simultaneously the integrity of the cells is maintained; and the other virus antigens inside are not contacted with the sample, so that the specificity of the neutralizing antibodies in determination can be guaranteed. The kit can be directly used for fast determination of the titer of the neutralizing antibodies in VZV on an automatic biochemical analyzer or an enzyme labeling instrument; the determination process is simple and fast, the flux of the determined sample is high and quantitative determination can be realized.

The present invention relates to immunoreactive peptides that are homologous with the region encompassing amino acid positions 450 to 655 of glycoprotein II of varicella zoster virus. In this context, preference is given to those peptides corresponding to segments of amino acids 505 to 647, 517 to 597, 535 to 584 or 545 to 582. The immunoreactive peptides are useful for methods of diagnosing varicella zoster virus infection.

The invention relates to a varicella zoster virus gE protein mutant and an expression method thereof. Specifically, the invention discloses a protein with immunogenicity and a coding gene thereof. Theinvention also discloses a preparation method of the protein with immunogenicity.

The invention provides a varicella-zoster virus vaccine and application thereof, and belongs to the technical field of vaccines. The varicella-herpes zoster virus vaccine comprises liposome nano-particles, herpes zoster virus glycoprotein E and an adjuvant, wherein the herpes zoster virus glycoprotein E and the adjuvant are entrapped in the liposome nano-particles; the adjuvant comprises triterpenoid saponin. In the invention, after the herpes zoster virus glycoprotein E (gE) is wrapped by the liposome nanoparticles, antigen presenting cell phagocytosis and efficient antigen delivery can be effectively promoted, and sustained release of the vaccine is realized to continuously stimulate a body to generate specific cellular immune response aiming at VZV-gE. The triterpenoid saponin used in the invention can effectively realize cross presentation of antigen herpes zoster virus glycoprotein E and induce antigen-specific cellular immune response. Moreover, cholesterol rich in the lipid nanoparticles can effectively neutralize the cytotoxicity of the triterpenoid saponin, so that the safety of the vaccine is ensured.

The invention provides two recombinant adenoviruses for expressing gE protein of varicella-zoster virus and application, and relates to the technical field of biological medicine. The invention provides two recombinant adenoviruses prepared on the basis of the nucleotide sequence of the varicella-zoster virus gE protein, and the recombinant adenoviruses capable of expressing the varicella-zoster virus gE protein are homologous or heterologous combined as the herpes zoster virus vaccine. The immunopotentiator can induce the body to generate strong cellular and humoral immune response in a short time on a mouse.

The invention discloses a high-yield varicella virus culture method. The method specifically comprises the following steps of: S1, cell resuscitation: carrying out cell resuscitation passage on a working cell bank MRC-5 from ATCC, taking an M199-801 culture solution containing 10-20% of newborn calf serum as a cell growth solution, carrying out culture at 37 DEG C with 5% of CO2, and after 3-4 days, enabling cells to grow all over a single layer and preparing for passage of the next generation; S2, cell passage: washing the surfaces of the cells twice by using a 0.01 mol / L PBS (Phosphate Buffer Solution); adding a proper amount of a pre-heated EDTA-Trypsin digestive juice; observing a gap on a cell surface by naked eyes; removing digestive juice, adding a small amount of a cell culture fluid, blowing and beating to uniformly disperse cells, carrying out passage according to a ratio of 1: 4-1: 8, finally carrying out passage on the cells into a Corning HYPERStack culture room, supplementing a 5-10% newborn calf serum M199-801 culture solution with a concentration of 0.2-0.3 ml / cm<2>, and culturing at 37 DEG C with 5% CO2. The invention relates to the technical field of biological medicines. According to the high-yield varicella virus culture method, under the production scale, after the method is adopted, the production yield is increased by about 100%, and the production cost is reduced by about 40%-50%.

The invention relates to the field of nucleic acid vaccines, in particular to a varicella-herpes zoster mRNA vaccine and a preparation method and application thereof. The mRNA for coding the varicella-zoster virus antigen provided by the invention contains a coding region for coding glycoprotein E of the varicella-zoster virus, and the mRNA can induce specific antibody response and CD4 + T cell response aiming at the glycoprotein E when being delivered into a body.

The invention provides an antibody for detecting varicella-zoster virus (VZV) titer and a related detection method. The method comprises the following steps: inoculating diploid cells into a 96-well plate, culturing, infecting a sample inoculated with unknown virus titer, culturing, adding an antibody specifically combined with VZV virus and an FITC labeled secondary antibody, carrying out fluorescence staining, and observing the infected lesion number under a microscope to obtain the virus titer of the sample. The method provided by the invention is strong in specificity, sensitive, rapid andeasy to observe, can obtain the same detection accuracy as a traditional speckle method, and can significantly shorten the detection time.

The invention discloses a preparation method of a varicella-zoster virus vaccine. The preparation method comprises the following specific preparation steps: carrying out centrifugal separation on harvested cell sap, a UniFuge disposable barrel-shaped bowl body centrifugal machine is adopted for centrifugal separation, in addition, the method further comprises the procedures of cell recovery, cellpassage, virus culture, cell harvesting and centrifugal washing. According to the invention, the problems of high cell collection and washing sterile operation risk and poor bovine serum albumin washing and removal effect in the varicella-zoster virus vaccine production process in the prior art can be solved.

The present invention provides genetically engineered cell lines, recombinant vectors, and vaccines. The present invention also provides methods for generating an in vitro system for Varicella zoster virus (VZV), and the in vitro systems generated by these methods. The present invention further provides methods for reactivating VZV, and VZV reactivated by these methods. Finally, the present invention provides a method of screening for an agent for treating VZV infection.

At present, the whole world is a lack of clinically high-efficient and safe broad-spectrum antiviral drugs. A composite of total riboside proteosome component that is prepared from plant chickweed or another stellaria plant and extracted by two resin adsorption methods and a hydroalcohol through a hyperfiltration method, has a molecular weight of 1,000 to 100,000 and is in the form of dark brown powder is used as a safer and more high-efficient broad-spectrum antiviral natural drug. The total protein of the total riboside proteosome component takes up 15% to 25% in the chemical construction, and is made up of 17 amino acids, such as asparaginic acid, glutamic acid, serine, histidine, cystine, methionine, isoleucine and the like in proportions; the proportion of sugar comprises ribose, glucose, galactose and arabinose, and total ribonucleotide takes up 5% to 10% and comprises uracil, thymine, thymidine, guanosine, 2-chloro-adenosine. The composite can be used as a drug for treating virus diseases, such as AIDS virus, hepatitis virus, respiratory syncytial viruses like influenza virus, parainfluenza virus, adenovirus, and the like, including highlypathogenic avian influenza virus, and condyloma virus, enterovirus, mumps virus, herpes simplex virus, herpes zoster virus and varicella-zoster virus. Moreover, the composite has no toxicity, and can be made into more than 10 types of medicine preparations, health products and the like, while causing no environmental pollution in the production process.

The invention provides immunochromatography detection test paper for a fluorescently-labeled varicella-zoster virus and application of the immunochromatography detection test paper. The test paper comprises a supporting bottom plate and an adsorption layer fixed on the supporting bottom plate, wherein the adsorption layer sequentially comprises a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad from a test end; the nitrocellulose membrane contains a detection line T and a quality control line print; a monoclonal antibody 7E12 marked by quantum dots is marked on the combination pad; a monoclonal antibody 5B10 is marked by the detection line T; sPA is marked by the quality control line. Wherein the monoclonal antibody 7E12 and the monoclonal antibody 5B10 are prepared by using a gE protein as an antigen. The glycoprotein gE monoclonal antibody can specifically recognize and resist the varicella-zoster virus glycoprotein gE protein and the varicella-zoster virus, and can be used for detecting the varicella-zoster virus glycoprotein gE and the varicella-zoster virus.

An antigen variant and a use thereof are disclosed. The antigen variant is a protein, among surface proteins (gE) of the varicella zoster virus, exhibits a high expression level and high immunogenicity, and thus, when the antigen variant is used as a vaccine composition, the vaccine composition has more excellent safety compared to a live virus vaccine, and the antigen variant exhibits a higher expression level in a host cell compared to other antigens. The antigen variant is useful as a vaccine for preventing or treating chicken pox or herpes zoster caused by the varicella zoster virus.

The invention relates to a VZV infection diagnosis and detection kit based on a chemiluminescence immunoassay method. According to the present invention, with the automated chemiluminescence immunoassay technology, the specific varicella-zoster virus antibodies such as immunoglobulin isoforms G, A and M (IgG, IgA and IgM) can be detected so as to diagnose diseases related to varicella-zoster virus infection. The kit provided by the invention is also suitable for screening various subjects suspected of diseases or symptoms related to VZV infection.

The invention provides the use of rosmarinic acid in the preparation of medicines for inhibiting varicella-zoster virus. The rosmarinic acid of the present invention has significant inhibitory effect on VZV, can be used to prepare medicines for inhibiting varicella-zoster virus (VZV), and can also be used to prepare medicines for treating infectious diseases caused by varicella-zoster virus, Such diseases include chickenpox and herpes zoster, postherpetic neuralgia, varicella pneumonia, and acute cerebellar ataxia and encephalitis caused by the varicella-zoster virus, among others.

The invention discloses application of thymidylate synthase as the target in screening anti-herpes virus drugs. thymidylate synthase can be used for screening drugs resisting Herpes simplex virus-1 (HSV-1), Herpes simplex virus-2 (HSV-2), Varicella zoster virus (VZV), EB virus (Epstein-Barr virus, EBV), Cytomegalovirus (CMV), human herpes virus type VI (HHV-6), human herpes virus type VII (HHV-7) and Kaposi's sarcoma-associated herpesvirus (KSHV) and other herpes viruses. The cell target thymidylate synthase involved in the invention can be used as a new anti-herpes virus target for drug development, and can be applied to treatment or prevention of herpes virus infection.

The invention discloses anti-varicella-zoster virus siRNAs. The anti-varicella-zoster virus siRNAs comprise a positive-sense strand and an antisense strand which are complementary, wherein the nucleotide sequence of the positive-sense strand is one of sequences shown in SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27 and 29, or is a sequence which has the similarity of 90 percent or above with one of the nucleotide sequences of the positive-sense strand; and the nucleotide sequence of the antisense strand of the siRNAs is one of 15 sequences corresponding to the positive-sense strand respectively, or is a complementary sequence of a sequence which has the similarity of 90 percent or above with one of the nucleotide sequences of the positive-sense strand. Moreover, the invention further discloses application of the anti-varicella-zoster virus siRNAs. The siRNAs disclosed by the invention have very high biological activity, can remarkably inhibit replication of varicella-zoster virus, and have the advantages of high functionality and the like.